Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 0.57 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 15/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 14/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2507030 | 0.90 | PIK3CD (0.58) | PIK3CDPIK3R1PIK3CBPIK3CGCYP11B2 | |
| SCHEMBL2553878 | 0.90 | PIK3CD (0.58) | PIK3CDPIK3R1PIK3CBPIK3CGCYP11B2 | |
| SCHEMBL2510619 | 0.83 | PIK3CD (0.57) | PIK3CDPIK3R1PIK3CBPIK3CGCYP11B2 | |
| SCHEMBL12196845 | 0.81 | PIK3CD (0.54) | PIK3CDPIK3R1PIK3CBPIK3CGCYP11B2 | |
| SCHEMBL2505115 | 0.75 | PIK3CD (1.00) | PIK3CDPIK3R1PIK3CBPIK3CG | |
| SCHEMBL12265568 | 0.75 | PIK3CD (0.49) | PIK3CDPIK3R1PIK3CBPIK3CGCYP11B2 | |
| SCHEMBL2508106 | 0.75 | PIK3CD (1.00) | PIK3CDPIK3R1PIK3CBPIK3CG | |
| SCHEMBL12197126 | 0.73 | PIK3CD (0.60) | PIK3CDPIK3R1PIK3CBPIK3CGCYP11B2 | |
| SCHEMBL16160311 | 0.72 | CYP11B1 (0.48) | PIK3CDPIK3R1PIK3CBPIK3CGCYP11B2 | |
| SCHEMBL2551721 | 0.72 | CYP11B1 (0.44) | PIK3CDPIK3R1PIK3CBPIK3CGCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575183-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 16/4885PIK3R1 48/4885PIK3CB 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.